William Blair analyst Ryan Daniels last night downgraded Agilon Health (AGL) to Market Perform from Outperform without a price target The company reported Q3 results that were largely in line with expectations on sales but well below on the adjusted EBITDA line and management also reduced 2024 profit expectations to account for negative prior-period developments and higher current year cost trends, the analyst tells investors in a research note. The firm sees limited investor enthusiasm in the near term driven by elevated medical costs, which should prove transitory, and a lack of visibility on a turnaround.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Reports Growth Amidst Financial Challenges
- Agilon Health downgraded to Market Perform from Outperform at William Blair
- Agilon Health Reports Revenue Rise Despite Net Loss
- Agilon Health reports Q3 EPS (29c), consensus (11c)
- Agilon Health cuts FY24 adjusted EBITDA to (155M)-(135M) from (60M)-(15)